Ropes & Gray represented Perceptive Xontogeny Venture Funds in a strategic partnership with Lexeo Therapeutics and venBio Partners to develop novel RNA-based therapeutics for genetic cardiac diseases through a new entity backed by up to $40 million in private equity financing from Perceptive and venBio. The partnership was announced on June 24.
The collaboration will combine Lexeo’s experience in cardiac genetic medicines with a novel non-viral RNA delivery platform to address cardiovascular conditions that current adeno-associated virus (AAV) platforms cannot treat.
Under the agreement, Lexeo will receive a double-digit percentage equity stake in the new entity and will be entitled to future milestone payments, royalties, and opt-in rights to certain programs.
The Ropes & Gray team was led by life sciences licensing partner Hannah England, emerging companies & venture capital counsel Ray Grant, life sciences licensing associate Ian Nilsen, and emerging companies & venture capital associate Joe Muller.
The team also included tax partner Pam Glazier and emerging companies & venture capital associates David Marino, Michelle Kelrikh, James Gould and Nora Ghanem.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.